HealthCentral acquires Wellsphere

Share this article:
HealthCentral acquires Wellsphere
HealthCentral acquires Wellsphere

HealthCentral has acquired Wellsphere, a health and wellness information and technology firm. Wellsphere will add close to four million unique viewers per month to HealthCentral's network of properties. Terms of the deal were not disclosed.

Wellsphere brings an aggregated 1,500 health and wellness bloggers into the fold, in addition to its “Health Knowledge Engine” which identifies and organizes related health content for consumers, according to Jeremy Shane, president and COO at HealthCentral.

Wellsphere's bloggers may be monetized through the placement of banners and other advertising, said Shane, but the bloggers will also deliver “access to an audience of influentials, that can potentially redistribute HealthCentral's messaging.”

In that capacity, a stable of bloggers would complement HealthCentral's professional writers, whose medically reviewed columns drive content, and carry banner inventory for pharmas, explained Shane. Wellsphere's organizational technology deciphers specific content and serves it to consumers, pairing individual inquiries with longtail health information for actionable results, he said.

Additionally, Wellsphere has developed a series of consumer tools such as “Wellphone,” a mobile platform, “WellPages,” a personalized account service and “Wellternatives,” a tool that provides nutritional information about menus from restaurants across the country.

With the addition of four million unique viewers (UV) per month, HealthCentral's network of properties could reach nearly 10 million UV in the coming months. However, Shane says UV count isn't everything. “It's about performance of scale, not ‘the biggest is the best.' That's the game,” he said.

HealthCentral's title property, healthcentral.com, is one of over 30 condition-specific websites owned by the company.

Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.